The delivery of therapeutic peptides via the oral route remains one of the biggest challenges in the pharmaceutical industry. Recently, we have described an alternative improved drug delivery system for peptide delivery via the oral route, consisting of a lipidic nanocapsule. Despite the striking effects observed, it is still essential to develop strategies to strengthen the nanocarriers’ glucagon-like peptide-1 (GLP-1) secretory effect of the nanocarrier and/or prolong its anti-diabetic effect in vivo to facilitate its translation into the clinic. To investigate a potential difference in mucus diffusion, single particle tracking was performed.
Read more:
Xu, Y., De Keersmaecker, H., Braeckmans, K., De Smedt, S., Cani, P. D., Préat, V., & Beloqui, A. (2020). Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment. Biomaterials, 255, 120209. https://doi.org/10.1016/j.biomaterials.2020.120209
Comments